274 related articles for article (PubMed ID: 16752933)
1. Dose adaptation of antineoplastic drugs in patients with liver disease.
Tchambaz L; Schlatter C; Jakob M; Krähenbühl A; Wolf P; Krähenbühl S
Drug Saf; 2006; 29(6):509-22. PubMed ID: 16752933
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.
Schlatter C; Egger SS; Tchambaz L; Krähenbühl S
Drug Saf; 2009; 32(7):561-78. PubMed ID: 19530743
[TBL] [Abstract][Full Text] [Related]
3. Dose adjustment in patients with liver disease.
Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
[TBL] [Abstract][Full Text] [Related]
4. The effects of impaired liver function on the elimination of antineoplastic agents.
Koren G; Beatty K; Seto A; Einarson TR; Lishner M
Ann Pharmacother; 1992 Mar; 26(3):363-71. PubMed ID: 1554959
[TBL] [Abstract][Full Text] [Related]
5. [Hepatic tolerance of atypical antipsychotic drugs].
Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity of chemotherapy.
King PD; Perry MC
Oncologist; 2001; 6(2):162-76. PubMed ID: 11306728
[TBL] [Abstract][Full Text] [Related]
7. Drug dosage recommendations in patients with chronic liver disease.
Periáñez-Párraga L; Martínez-López I; Ventayol-Bosch P; Puigventós-Latorre F; Delgado-Sánchez O
Rev Esp Enferm Dig; 2012 Apr; 104(4):165-84. PubMed ID: 22537365
[TBL] [Abstract][Full Text] [Related]
8. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
9. Part I: Liver function in oncology: biochemistry and beyond.
Field KM; Dow C; Michael M
Lancet Oncol; 2008 Nov; 9(11):1092-101. PubMed ID: 19012858
[TBL] [Abstract][Full Text] [Related]
10. [Hepatic failure and renal failure in antineoplastic chemotherapy, and its treatment].
Nakao I
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2930-8. PubMed ID: 3767385
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of antidepressants in patients with hepatic impairment.
Mauri MC; Fiorentini A; Paletta S; Altamura AC
Clin Pharmacokinet; 2014 Dec; 53(12):1069-81. PubMed ID: 25248846
[TBL] [Abstract][Full Text] [Related]
12. A physiologically-based flow network model for hepatic drug elimination III: 2D/3D DLA lobule models.
Rezania V; Coombe D; Tuszynski JA
Theor Biol Med Model; 2016 Mar; 13():9. PubMed ID: 26939615
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of anticancer agents in patients with impaired liver function.
Donelli MG; Zucchetti M; Munzone E; D'Incalci M; Crosignani A
Eur J Cancer; 1998 Jan; 34(1):33-46. PubMed ID: 9624235
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in the elderly: pharmacologic considerations.
Lichtman SM; Villani G
Cancer Control; 2000; 7(6):548-56. PubMed ID: 11088063
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced hepatotoxicity in cancer patients - implication for treatment.
Vincenzi B; Armento G; Spalato Ceruso M; Catania G; Leakos M; Santini D; Minotti G; Tonini G
Expert Opin Drug Saf; 2016 Sep; 15(9):1219-38. PubMed ID: 27232067
[TBL] [Abstract][Full Text] [Related]
16. Treatment regimens of classical and newer taxanes.
Joerger M
Cancer Chemother Pharmacol; 2016 Feb; 77(2):221-33. PubMed ID: 26589792
[TBL] [Abstract][Full Text] [Related]
17. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Twelves C; Glynne-Jones R; Cassidy J; Schüller J; Goggin T; Roos B; Banken L; Utoh M; Weidekamm E; Reigner B
Clin Cancer Res; 1999 Jul; 5(7):1696-702. PubMed ID: 10430071
[TBL] [Abstract][Full Text] [Related]
18. Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.
González J; Quiroga M; Escudero-Vilaplana V; Collado-Borrell R; Herranz-Alonso A; Sanjurjo Sáez M
Expert Opin Drug Saf; 2018 Jun; 17(6):553-572. PubMed ID: 29781751
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
Morgan DJ; McLean AJ
Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
[TBL] [Abstract][Full Text] [Related]
20. Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats.
Zhao Y; Zhai D; Chen X; Yang J; Song X; He H; Yu Q; Xing Y
Toxicology; 2007 Feb; 230(2-3):145-50. PubMed ID: 17184895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
